TELADOC HEALTH INC (TDOC) Fundamental Analysis & Valuation

NYSE:TDOC • US87918A1051

Current stock price

5.35 USD
-0.17 (-3.08%)
At close:
5.4487 USD
+0.1 (+1.84%)
After Hours:

This TDOC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. TDOC Profitability Analysis

1.1 Basic Checks

  • In the past year TDOC has reported negative net income.
  • In the past year TDOC had a positive cash flow from operations.
  • In the past 5 years TDOC always reported negative net income.
  • In the past 5 years TDOC always reported a positive cash flow from operatings.
TDOC Yearly Net Income VS EBIT VS OCF VS FCFTDOC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5B -10B

1.2 Ratios

  • Looking at the Return On Assets, with a value of -7.01%, TDOC is in line with its industry, outperforming 57.14% of the companies in the same industry.
  • With a Return On Equity value of -14.46%, TDOC perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
ROA -7.01%
ROE -14.46%
ROIC N/A
ROA(3y)-13.5%
ROA(5y)-71.46%
ROE(3y)-30.36%
ROE(5y)-137.12%
ROIC(3y)N/A
ROIC(5y)N/A
TDOC Yearly ROA, ROE, ROICTDOC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400 -500

1.3 Margins

  • With a decent Gross Margin value of 69.50%, TDOC is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • TDOC's Gross Margin has improved in the last couple of years.
  • TDOC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.5%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.2%
GM growth 5Y1.58%
TDOC Yearly Profit, Operating, Gross MarginsTDOC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. TDOC Health Analysis

2.1 Basic Checks

  • TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TDOC has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TDOC has been increased compared to 5 years ago.
  • Compared to 1 year ago, TDOC has an improved debt to assets ratio.
TDOC Yearly Shares OutstandingTDOC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
TDOC Yearly Total Debt VS Total AssetsTDOC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.2 Solvency

  • TDOC has an Altman-Z score of -6.66. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
  • TDOC's Altman-Z score of -6.66 is on the low side compared to the rest of the industry. TDOC is outperformed by 80.00% of its industry peers.
  • The Debt to FCF ratio of TDOC is 7.24, which is on the high side as it means it would take TDOC, 7.24 years of fcf income to pay off all of its debts.
  • With a Debt to FCF ratio value of 7.24, TDOC perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
  • TDOC has a Debt/Equity ratio of 0.72. This is a neutral value indicating TDOC is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.72, TDOC is not doing good in the industry: 77.14% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 7.24
Altman-Z -6.66
ROIC/WACCN/A
WACC6.99%
TDOC Yearly LT Debt VS Equity VS FCFTDOC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.77 indicates that TDOC has no problem at all paying its short term obligations.
  • TDOC has a better Current ratio (2.77) than 68.57% of its industry peers.
  • TDOC has a Quick Ratio of 2.67. This indicates that TDOC is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of TDOC (2.67) is better than 65.71% of its industry peers.
Industry RankSector Rank
Current Ratio 2.77
Quick Ratio 2.67
TDOC Yearly Current Assets VS Current LiabilitesTDOC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. TDOC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 8.06% over the past year.
  • The Revenue has decreased by -1.54% in the past year.
  • The Revenue has been growing by 18.26% on average over the past years. This is quite good.
EPS 1Y (TTM)8.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-1.54%
Revenue growth 3Y1.68%
Revenue growth 5Y18.26%
Sales Q2Q%0.28%

3.2 Future

  • TDOC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.91% yearly.
  • The Revenue is expected to grow by 3.45% on average over the next years.
EPS Next Y22.51%
EPS Next 2Y15.59%
EPS Next 3Y8.7%
EPS Next 5Y10.91%
Revenue Next Year-0.43%
Revenue Next 2Y0.41%
Revenue Next 3Y0.73%
Revenue Next 5Y3.45%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TDOC Yearly Revenue VS EstimatesTDOC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B
TDOC Yearly EPS VS EstimatesTDOC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

2

4. TDOC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TDOC. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TDOC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TDOC Price Earnings VS Forward Price EarningsTDOC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

  • 91.43% of the companies in the same industry are more expensive than TDOC, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, TDOC is valued cheaply inside the industry as 94.29% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 6.95
EV/EBITDA 5.82
TDOC Per share dataTDOC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.59%
EPS Next 3Y8.7%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TDOC Dividend Analysis

5.1 Amount

  • TDOC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TDOC Fundamentals: All Metrics, Ratios and Statistics

TELADOC HEALTH INC

NYSE:TDOC (3/20/2026, 8:24:44 PM)

After market: 5.4487 +0.1 (+1.84%)

5.35

-0.17 (-3.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)02-25
Earnings (Next)04-28
Inst Owners74.53%
Inst Owner Change5.55%
Ins Owners0.55%
Ins Owner Change1.89%
Market Cap954.44M
Revenue(TTM)2.53B
Net Income(TTM)-200.32M
Analysts68.82
Price Target8.88 (65.98%)
Short Float %17.86%
Short Ratio4.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.85%
Min EPS beat(2)-3.18%
Max EPS beat(2)26.88%
EPS beat(4)2
Avg EPS beat(4)-0.46%
Min EPS beat(4)-54.19%
Max EPS beat(4)28.67%
EPS beat(8)4
Avg EPS beat(8)4.17%
EPS beat(12)8
Avg EPS beat(12)7.08%
EPS beat(16)10
Avg EPS beat(16)-744.49%
Revenue beat(2)0
Avg Revenue beat(2)-1.38%
Min Revenue beat(2)-1.88%
Max Revenue beat(2)-0.88%
Revenue beat(4)0
Avg Revenue beat(4)-0.9%
Min Revenue beat(4)-1.88%
Max Revenue beat(4)-0.35%
Revenue beat(8)0
Avg Revenue beat(8)-1.2%
Revenue beat(12)0
Avg Revenue beat(12)-1.45%
Revenue beat(16)0
Avg Revenue beat(16)-1.47%
PT rev (1m)0%
PT rev (3m)-4.16%
EPS NQ rev (1m)-28%
EPS NQ rev (3m)-31.88%
EPS NY rev (1m)-12.7%
EPS NY rev (3m)-16.26%
Revenue NQ rev (1m)-3.12%
Revenue NQ rev (3m)-2.92%
Revenue NY rev (1m)-1.42%
Revenue NY rev (3m)-1.46%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.38
P/FCF 6.95
P/OCF 3.24
P/B 0.69
P/tB N/A
EV/EBITDA 5.82
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)0.77
FCFY14.39%
OCF(TTM)1.65
OCFY30.84%
SpS14.18
BVpS7.77
TBVpS-1.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.01%
ROE -14.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.5%
FCFM 5.43%
ROA(3y)-13.5%
ROA(5y)-71.46%
ROE(3y)-30.36%
ROE(5y)-137.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.2%
GM growth 5Y1.58%
F-Score5
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.72
Debt/FCF 7.24
Debt/EBITDA 4.96
Cap/Depr 43.13%
Cap/Sales 6.21%
Interest Coverage N/A
Cash Conversion 146.68%
Profit Quality N/A
Current Ratio 2.77
Quick Ratio 2.67
Altman-Z -6.66
F-Score5
WACC6.99%
ROIC/WACCN/A
Cap/Depr(3y)40.79%
Cap/Depr(5y)44.08%
Cap/Sales(3y)5.68%
Cap/Sales(5y)5.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y22.51%
EPS Next 2Y15.59%
EPS Next 3Y8.7%
EPS Next 5Y10.91%
Revenue 1Y (TTM)-1.54%
Revenue growth 3Y1.68%
Revenue growth 5Y18.26%
Sales Q2Q%0.28%
Revenue Next Year-0.43%
Revenue Next 2Y0.41%
Revenue Next 3Y0.73%
Revenue Next 5Y3.45%
EBIT growth 1Y21.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year215.69%
EBIT Next 3Y48.4%
EBIT Next 5Y28.54%
FCF growth 1Y-19.04%
FCF growth 3Y102.66%
FCF growth 5YN/A
OCF growth 1Y0.23%
OCF growth 3Y15.85%
OCF growth 5YN/A

TELADOC HEALTH INC / TDOC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of TELADOC HEALTH INC (TDOC) stock?

ChartMill assigns a fundamental rating of 3 / 10 to TDOC.


What is the valuation status for TDOC stock?

ChartMill assigns a valuation rating of 2 / 10 to TELADOC HEALTH INC (TDOC). This can be considered as Overvalued.


How profitable is TELADOC HEALTH INC (TDOC) stock?

TELADOC HEALTH INC (TDOC) has a profitability rating of 3 / 10.


How financially healthy is TELADOC HEALTH INC?

The financial health rating of TELADOC HEALTH INC (TDOC) is 4 / 10.